抗鼠科肉瘤病毒癌基因同源物B1突变与甲状腺乳头状癌淋巴结转移的关系研究进展

近年来随着检查设备敏感性的提高及人们生活、饮食环境的改变,甲状腺癌(TC)的发病率直线上升,10年内增加了近5倍,不同病理类型甲状腺癌发病机制、临床表现、生物学行为、治疗方法和预后有明显不同。甲状腺乳头状癌(PTC)任何年龄均可发病,约占甲状腺癌的90%,疾病进展缓慢,预后良好,但易出现淋巴结转移。是否伴有淋巴结转移对于PTC的预后转归有着重要影响,抗鼠科肉瘤病毒癌基因同源物B1(BRAF)基因突变在PTC的淋巴结转移中发挥着至关重要的作用,深入了解BRAF基因突变在PTC的具体作用及机制,有望对PTC提供新的诊疗思路。

Research progress on the relationship between the Raf murine sarcoma viral oncogene homolog B gene mutation and lymph node metastasis of papillary thyroid carcinoma

In recent years,with the improvement of the sensitivity of examination equipment and the change of people’s living environment and diet,the rate of thyroid cancer has risen rapidly,which has increased nearly five folds in10 years.The pathogenesis,clinical manifestation,biological behavior,treatment and prognosis of thyroid carcinoma of different pathological types are obviously different.Papillary thyroid carcinoma(PTC)can develop at any age,which accounts for about 90%of thyroid cancer.It progresses slowly and has favourable prognosis,but lymph node metastasis appears easily.Whether PTC is accompanied by lymph node metastasis has an important impact on its prognosis and outcome.The Raf murine sarcoma viral oncogene homolog B(BRAF)gene mutation plays a crucial role in PTC lymph node metastasis.Having an in-depth understanding of the specific role and mechanism of BRAF gene mutation in PTC is expected to provide new ideas for diagnosis and treatment of PTC.